Uwe Siebert1, Gaby Sroczynski. 1. Institute of Medical Informatics, Biometry, and Epidemiology, Ludwig-Maximilians-University, Munich, Germany. usiebert@hsph.harvard.edu
Abstract
OBJECTIVES: The purpose of this health technology assessment (HTA), commissioned by the German Federal Ministry of Health and Social Security, was to systematically review the evidence for the effectiveness and cost-effectiveness of antiviral treatment (AVT) with interferon (INF) or peginterferon (PegIFN) in combination with ribavirin (RBV) in treatment-naïve patients with chronic hepatitis C (CHC) and to apply these data in the context of the German health-care system. METHODS: We performed a systematic literature search on effectiveness and cost-effectiveness of AVT and summarized results using meta-analysis and evidence tables. We applied the German Hepatitis C Model (GEHMO), a decision-analytic Markov model, to determine long-term clinical effectiveness, costs, and incremental cost-effectiveness ratios (ICER) of the examined treatment strategies. Model parameters were derived from German databases, published international randomized clinical trials (RCT), and a Cochrane Review. RESULTS: Overall, nine RCTs, two HTA reports, one Cochrane review, two meta-analyses, and seven economic evaluations met the inclusion criteria. These studies indicate that PegIFN + RBV achieved the highest sustained virological response rates (SVR) (54-61 percent), followed by IFN + RBV (38-54 percent) and IFN monotherapy (11-21 percent). Based on our meta-analysis, PegIFN + RBV reduced cases without SVR by 17 percent compared with INF + RBV. International cost-effectiveness studies indicate that INF+ RBV is cost-effective when compared with INF monotherapy. For PegIFN + RBV, our decision analysis yielded an ICER of 9,800 Euros per quality-adjusted life-year gained. CONCLUSIONS: This HTA suggests that initial combination therapy prolongs life, improves quality of life, and is cost-effective in patients with CHC. Peginterferon plus ribavirin is the most effective and efficient treatment among the examined options. However, because not all chronic hepatitis C patients will develop progressive liver disease, a thorough assessment of the eligibility and appropriateness of treatment with combination therapy must be performed in each individual patient.
OBJECTIVES: The purpose of this health technology assessment (HTA), commissioned by the German Federal Ministry of Health and Social Security, was to systematically review the evidence for the effectiveness and cost-effectiveness of antiviral treatment (AVT) with interferon (INF) or peginterferon (PegIFN) in combination with ribavirin (RBV) in treatment-naïve patients with chronic hepatitis C (CHC) and to apply these data in the context of the German health-care system. METHODS: We performed a systematic literature search on effectiveness and cost-effectiveness of AVT and summarized results using meta-analysis and evidence tables. We applied the German Hepatitis C Model (GEHMO), a decision-analytic Markov model, to determine long-term clinical effectiveness, costs, and incremental cost-effectiveness ratios (ICER) of the examined treatment strategies. Model parameters were derived from German databases, published international randomized clinical trials (RCT), and a Cochrane Review. RESULTS: Overall, nine RCTs, two HTA reports, one Cochrane review, two meta-analyses, and seven economic evaluations met the inclusion criteria. These studies indicate that PegIFN + RBV achieved the highest sustained virological response rates (SVR) (54-61 percent), followed by IFN + RBV (38-54 percent) and IFN monotherapy (11-21 percent). Based on our meta-analysis, PegIFN + RBV reduced cases without SVR by 17 percent compared with INF + RBV. International cost-effectiveness studies indicate that INF+ RBV is cost-effective when compared with INF monotherapy. For PegIFN + RBV, our decision analysis yielded an ICER of 9,800 Euros per quality-adjusted life-year gained. CONCLUSIONS: This HTA suggests that initial combination therapy prolongs life, improves quality of life, and is cost-effective in patients with CHC. Peginterferon plus ribavirin is the most effective and efficient treatment among the examined options. However, because not all chronic hepatitis Cpatients will develop progressive liver disease, a thorough assessment of the eligibility and appropriateness of treatment with combination therapy must be performed in each individual patient.
Authors: A I Soipe; H Razavi; D Razavi-Shearer; O Galárraga; L E Taylor; B D L Marshall Journal: Epidemiol Infect Date: 2016-08-05 Impact factor: 2.451
Authors: Roger T Anderson; Robert W Baran; Birgitta Dietz; Eric Kallwitz; Pennifer Erickson; Dennis A Revicki Journal: Qual Life Res Date: 2013-09-05 Impact factor: 4.147
Authors: David B Rein; John S Wittenborn; Bryce D Smith; Danielle K Liffmann; John W Ward Journal: Clin Infect Dis Date: 2015-03-16 Impact factor: 9.079
Authors: Uwe Siebert; Gaby Sroczynski; Pamela Aidelsburger; Siegbert Rossol; Jürgen Wasem; Michael P Manns; John G McHutchison; John B Wong Journal: Pharmacoeconomics Date: 2009 Impact factor: 4.981
Authors: Jörn M Schattenberg; Jeffrey V Lazarus; Philip N Newsome; Lawrence Serfaty; Alessio Aghemo; Salvador Augustin; Emmanuel Tsochatzis; Victor de Ledinghen; Elisabetta Bugianesi; Manuel Romero-Gomez; Heike Bantel; Stephen D Ryder; Jerome Boursier; Vincent Leroy; Javier Crespo; Laurent Castera; Lefteris Floros; Vincenzo Atella; Jorge Mestre-Ferrandiz; Rachel Elliott; Achim Kautz; Alice Morgan; Sally Hartmanis; Sharad Vasudevan; Lynne Pezzullo; Aldo Trylesinski; Sandrine Cure; Victoria Higgins; Vlad Ratziu Journal: Liver Int Date: 2021-03-18 Impact factor: 5.828